about
CART regulates islet hormone secretion and is expressed in the beta-cells of type 2 diabetic ratsSubmucosal microinfusion of endothelin and adrenaline mobilizes ECL-cell histamine in rat stomach, and causes mucosal damage: a microdialysis study.Hypothalamic-endocrine aspects in Huntington's disease.Ghrelin and motilin are cosecreted from a prominent endocrine cell population in the small intestine.Increased metabolism in the R6/2 mouse model of Huntington's disease.Serum levels of a subset of cytokines show high interindividual variability and are not altered in rats transgenic for Huntington´s diseaseCharacterisation of immune cell function in fragment and full-length Huntington's disease mouse modelsAntibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's diseaseA 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease.White Adipose Tissue Browning in the R6/2 Mouse Model of Huntington's Disease.JAK/STAT Signalling in Huntington's Disease Immune Cells.HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin.Neurohormonal regulation of histamine and pancreastatin secretion from isolated rat stomach ECL cells.Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model.A-like cells in the rat stomach contain ghrelin and do not operate under gastrin control.Orexin and psychiatric symptoms in suicide attempters.Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntington's Disease.Immunomodulation - a disease-modifying avenue for treatment of Huntington's disease?Orexin loss in Huntington's disease.Skeletal muscle atrophy in R6/2 mice - altered circulating skeletal muscle markers and gene expression profile changes.A critical evaluation of inflammatory markers in Huntington's Disease plasma.Plasma melatonin is reduced in Huntington's disease.Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease.IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.Testicular degeneration in Huntington disease.Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.Cocaine and amphetamine regulated transcript (CART) in suicide attempters.Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder.Flt3 ligand does not differentiate between Parkinsonian disorders.Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells. A histochemical, electron-microscopic and chemical studyIncreased levels of hemoglobin and alpha1-microglobulin in Huntington's disease
P50
Q28570725-BEE82008-CC9C-4E5E-A363-21670B598163Q33193188-DBBAACB6-7482-477A-B23B-34F9A4CDA78CQ33254802-6A75D4B3-3C72-43C7-8AB4-E3BC8693DC77Q33289036-45635613-A028-481C-B8EB-4A9AEC37B75FQ33301810-726C51F0-4D81-417C-99A0-46B76410B451Q33730187-E9F3BE76-9F3E-4B47-9256-A1474988D37EQ34674235-586EE0F0-72C2-4D6A-89C6-D547EEB46CDDQ35072824-7A9C813C-AE2A-4C65-8C63-E4E0D179B723Q35797126-32427ACE-3802-49E7-9393-79595B0DB1A8Q36093756-E2017FEF-4918-486C-8875-C94EA07F9CFCQ37410973-C4EF58DD-DAFE-40DE-83E4-CE9167884B73Q37697482-4D4FD240-1B21-4909-BCC2-B0571AE8B7ABQ39873112-CAA07AA5-3CF3-4573-9322-C63F38D2DFACQ42448842-EB1FA816-01FD-45A2-9DD4-66E3BBF1B513Q42456321-9DE30CFA-A22E-43AA-B2AE-51E8695783A2Q43625224-1E548F5C-5B94-4611-A266-BC1314C8A772Q44820278-6DF08F47-8E0C-47B2-B485-6915CADA2220Q45292519-11304982-63DA-4FFA-9E24-006F2B93AF37Q45294338-8A6C2C65-A212-400E-AD0F-4DCCDA0355DAQ45295272-5B53F405-5964-4EC1-BFEF-F3E65BACFE81Q45300505-0BF604C4-7410-465B-ACA4-E42D97D9058AQ45300721-C44394E0-7193-4B6D-B3FE-08752D1096C8Q45301381-C7BDAAC1-ACDC-4A6E-A6D7-EC9D2C40F574Q45301725-78B95436-A7F4-4029-B40F-940580E36FBBQ45303621-9555B096-AA27-42E3-A24F-7BEA649F65C6Q45304856-725AA93B-09CC-4390-A235-5984048542C8Q46096621-1F66E345-E159-46C3-9DDE-0E996343CC0CQ46838842-A6B4AF7E-5F18-4B22-93C0-C56523E3D389Q48475139-EFABFF69-B98B-44D7-AE77-9D4B7C444777Q48648358-AC27D9DA-20AC-4D29-A87E-A0FC4FE3561BQ73399863-0D5C5529-4AC2-4DDF-8B4F-686AD890786BQ95798522-D2A76C0D-88F7-4983-AD00-8D2AB4B647B0
P50
description
researcher
@en
wetenschapper
@nl
name
M Björkqvist
@en
M Björkqvist
@nl
type
label
M Björkqvist
@en
M Björkqvist
@nl
prefLabel
M Björkqvist
@en
M Björkqvist
@nl
P106
P31
P496
0000-0001-8550-0431